<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lamotrigine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00555</strong>&#160; (APRD00570)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder. For epilepsy it is used to treat partial seizures, primary and secondary tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome. Lamotrigine also acts as a mood stabilizer. It is the first medication since lithium granted Food and Drug Administration (<span class="caps">FDA</span>) approval for the maintenance treatment of bipolar type I. Chemically unrelated to other anticonvulsants, lamotrigine has relatively few side-effects and does not require blood monitoring. The exact way lamotrigine works is unknown. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00555/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00555/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00555.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00555.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00555.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00555.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00555.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00555">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Lamotrigina</td><td>Spanish</td><td>INN</td></tr><tr><td>Lamotrigine</td><td>French/German</td><td>INN</td></tr><tr><td>Lamotriginum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Convulsan</td><td>Actavis</td></tr><tr><td>Crisomet</td><td>Juste</td></tr><tr><td>Dafex</td><td>Phoenix</td></tr><tr><td>Daksol</td><td>Pharmavita</td></tr><tr><td>Danoptin</td><td>Pliva</td></tr><tr><td>Dezepil</td><td>Rafarm</td></tr><tr><td>Elmendos</td><td>GlaxoSmithKline</td></tr><tr><td>Epilepax</td><td>Ivax</td></tr><tr><td>Epimil</td><td>Ivax</td></tr><tr><td>Epiral</td><td>Zentiva</td></tr><tr><td>Epitec</td><td>Cipla Medpro</td></tr><tr><td>Epitrigine</td><td>Actavis</td></tr><tr><td>Labileno</td><td>GlaxoSmithKline</td></tr><tr><td>Lambipol</td><td>GlaxoSmithKline</td></tr><tr><td>Lamect</td><td>PharmaSwiss</td></tr><tr><td>Lameptil</td><td>Sandoz</td></tr><tr><td>Lameptil S</td><td>Sandoz</td></tr><tr><td>Lametec</td><td>Vitalchem</td></tr><tr><td>Lamez</td><td>Intas</td></tr><tr><td>Lamictal</td><td>GlaxoSmithKline</td></tr><tr><td>Lamictal CD</td><td>GlaxoSmithKline</td></tr><tr><td>Lamictal XR</td><td>GlaxoSmithKline</td></tr><tr><td>Lamictin</td><td>GlaxoSmithKline</td></tr><tr><td>Lamotrix</td><td>Glenmark</td></tr><tr><td>Larig</td><td>Rowex</td></tr><tr><td>Medotrigin</td><td>Medochemie</td></tr><tr><td>Mogine</td><td>Douglas</td></tr><tr><td>Trimolep</td><td>Psicofarma</td></tr><tr><td>Trogine</td><td>Ranbaxy</td></tr><tr><td>Xebarin</td><td>Dr Reddys</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Cionamat</td><td>Lamotrigine and Clonazepam</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticonvulsants">Anticonvulsants</a></li>
<li><a href="/mesh/calcium-channel-blockers">Calcium Channel Blockers</a></li>
<li><a href="/mesh/antidepressive-agents">Antidepressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>84057-84-1</td></tr><tr><th>Weight</th><td>Average: 256.091<br>Monoisotopic: 255.007850663</td></tr><tr><th>Chemical Formula</th><td>C<sub>9</sub>H<sub>7</sub>Cl<sub>2</sub>N<sub>5</sub></td></tr><tr><th>InChI Key</th><td>PYZRQGJRPPTADH-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Halobenzenes</td></tr><tr><th>Direct parent</th><td>Dichlorobenzenes</td></tr><tr><th>Alternative parents</th><td>Aminotriazines; Primary Aromatic Amines; Aryl Chlorides; Polyamines; Organochlorides</td></tr><tr><th>Substituents</th><td>aminotriazine; aryl chloride; primary aromatic amine; aryl halide; triazine; polyamine; organochloride; organohalogen; amine; primary amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the dichlorobenzenes. These are compounds containing a benzene with exactly two chlorine atoms attached to it.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the adjunctive treatment of partial seizures in epilepsy and generalized seizures of Lennox-Gastaut syndrome. Also for the maintenance treatment of bipolar I disorder and depression. </td></tr><tr><th>Pharmacodynamics</th><td>Lamotrigine, an antiepileptic drug (AED) of the phenyltriazine class, is chemically unrelated to existing antiepileptic drugs. Lamotrigine is also used in the treatment of depression and bipolar disorder. Lamotrigine is thought to exert its anticonvulsant effect by stabilizing presynaptic neuronal membranes. Lamotrigine inhibits sodium currents by selectively binding to the inactivated state of the sodium channel and subsequently suppresses the release of the excilatory amino acid, glutamate.</td></tr><tr><th>Mechanism of action</th><td>One proposed mechanism of action of Lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. <i>in vitro</i> pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels and/or calcium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate). Studies on lamotrigine show binding to sodium channels similar to local anesthetics. </td></tr><tr><th>Absorption</th><td>98%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>0.9 to 1.3 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>55%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Lamotrigine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003544" target="_blank">UDP-glucuronosyltransferase 1-4</a></li>
<li><a href="/biodb/bio_entities/BE0003677" target="_blank">UDP-glucuronosyltransferase 1-3</a></li></ul></td><td><a href="/metabolites/DBMET00466">lamotrigine-2-N-glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/475">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>25 +/- 10 hours (healthy individuals); 42.9 hours (chronic renal failure)</td></tr><tr><th>Clearance</th><td><ul>
	<li>Apparent plasma cl=0.44 mL/min/kg [healthy volunteers taking single-dose <span class="caps">LAMICTAL</span>]</li>
	<li>Apparent plasma cl=0.58 mL/min/kg [healthy volunteers taking multiple-dose <span class="caps">LAMICTAL</span>]</li>
	<li>Apparent plasma cl=0.30 mL/min/kg [healthy volunteers taking valproate and single-dose <span class="caps">LAMICTAL</span>]</li>
	<li>Apparent plasma cl=0.18 mL/min/kg [healthy volunteers taking valproate and multiple-dose <span class="caps">LAMICTAL</span>]</li>
	<li>Apparent plasma cl=1.1 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and single-dose <span class="caps">LAMICTAL</span>]</li>
	<li>Apparent plasma cl=1.12 mL/min/kg [Patients with epilepsy taking carbamazepine, phenytoin, phenobarbital, or primidone plus valproate and multiple-dose <span class="caps">LAMICTAL</span>]</li>
</ul></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>=250 (mg/kg) (in rat, mice); LD<sub>50</sub>&gt;640 orally (mg/kg) (in rat, mice) (Sawyer). Symptoms of overdose include decreased level of consciousness, coma, delayed heartbeat, increased seizures, lack of coordination, and rolling eyeballs.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7155</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.911</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9604</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8176</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.9162</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9055</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6862</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.611</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.7007</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8594</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7678</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5515</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8202
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7895
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7556 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9168
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li>
<li>Aurobindo pharma ltd</li>
<li>Dr reddys laboratories ltd</li>
<li>Glenmark generics ltd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Taro pharmaceutical industries ltd</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Watson laboratories inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Smithkline beecham corp</li>
<li>Smithkline beecham corp dba glaxosmithkline</li>
<li>Apotex inc</li>
<li>Cadista pharmaceuticals inc</li>
<li>Lupin ltd</li>
<li>Matrix laboratories ltd</li>
<li>Roxane laboratories inc</li>
<li>Torrent pharmaceuticals ltd</li>
<li>Upsher smith laboratories inc</li>
<li>Wockhardt ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://www.aurobindo.com">Aurobindo Pharma Ltd.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cadista.com">Cadista Pharmaceuticals Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.caremark.com">Caremark LLC</a></li>
<li><a href="http://www.cobaltpharma.com">Cobalt Pharmaceuticals Inc.</a></li>
<li><a href="http://www.compasspharma.com">Compass Pharma Services LLC</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li><a href="http://www.drreddys.com">Doctor Reddys Laboratories Ltd.</a></li>
<li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li>
<li><a href="http://www.glenmark-generics.com">Glenmark Generics Ltd.</a></li>
<li><a href="http://www.greenstonellc.com">Greenstone LLC</a></li>
<li>Heartland Repack Services LLC</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmacy Service Center</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li><a href="http://www.tarousa.com">Taro Pharmaceuticals USA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.torrentpharma.com">Torrent Pharmaceuticals</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>LaMICtal Starter 98 25 (84)-100(14)mg Kit Box</td><td>556.69USD</td><td>box</td></tr><tr><td>LaMICtal XR 200 mg 24 Hour tablet</td><td>12.11USD</td><td>tablet</td></tr><tr><td>Lamictal xr 200 mg tablet</td><td>11.65USD</td><td>tablet</td></tr><tr><td>LaMICtal XR 100 mg 24 Hour tablet</td><td>11.36USD</td><td>tablet</td></tr><tr><td>Lamictal xr 100 mg tablet</td><td>10.92USD</td><td>tablet</td></tr><tr><td>Lamictal xr 50 mg tablet</td><td>10.2USD</td><td>tablet</td></tr><tr><td>Lamictal 200 mg tablet</td><td>7.44USD</td><td>tablet</td></tr><tr><td>Lamictal odt start kt (orange)</td><td>7.28USD</td><td>tablet</td></tr><tr><td>Lamictal xr start kit (orange)</td><td>7.28USD</td><td>tablet</td></tr><tr><td>Lamictal odt 200 mg tablet</td><td>6.95USD</td><td>tablet</td></tr><tr><td>Lamictal odt 100 mg tablet</td><td>5.82USD</td><td>tablet</td></tr><tr><td>Lamotrigine 200 mg tablet</td><td>5.78USD</td><td>tablet</td></tr><tr><td>LaMICtal 25 mg Chew Tabs</td><td>5.63USD</td><td>tab</td></tr><tr><td>Lamictal odt 50 mg tablet</td><td>5.46USD</td><td>tablet</td></tr><tr><td>Lamictal tab start kit (green)</td><td>5.46USD</td><td>tablet</td></tr><tr><td>Lamictal 150 mg tablet</td><td>5.38USD</td><td>tablet</td></tr><tr><td>Lamictal odt 25 mg tablet</td><td>5.1USD</td><td>tablet</td></tr><tr><td>Lamictal xr 25 mg tablet</td><td>5.1USD</td><td>tablet</td></tr><tr><td>Lamictal 100 mg tablet</td><td>4.72USD</td><td>tablet</td></tr><tr><td>Lamotrigine tablet starter kit</td><td>4.24USD</td><td>tablet</td></tr><tr><td>Lamotrigine 150 mg tablet</td><td>3.98USD</td><td>tablet</td></tr><tr><td>Lamictal 25 mg tablet</td><td>3.78USD</td><td>tablet</td></tr><tr><td>Lamotrigine 100 mg tablet</td><td>3.52USD</td><td>tablet</td></tr><tr><td>LamoTRIgine 25 mg Chew Tabs</td><td>3.33USD</td><td>tab</td></tr><tr><td>LamoTRIgine 5 mg Chew Tabs</td><td>3.18USD</td><td>tab</td></tr><tr><td>Lamotrigine 25 mg tablet</td><td>2.9USD</td><td>tablet</td></tr><tr><td>Apo-Lamotrigine 150 mg Tablet</td><td>1.31USD</td><td>tablet</td></tr><tr><td>Mylan-Lamotrigine 150 mg Tablet</td><td>1.31USD</td><td>tablet</td></tr><tr><td>Novo-Lamotrigine 150 mg Tablet</td><td>1.31USD</td><td>tablet</td></tr><tr><td>Pms-Lamotrigine 150 mg Tablet</td><td>1.31USD</td><td>tablet</td></tr><tr><td>Ratio-Lamotrigine 150 mg Tablet</td><td>1.31USD</td><td>tablet</td></tr><tr><td>Apo-Lamotrigine 100 mg Tablet</td><td>0.88USD</td><td>tablet</td></tr><tr><td>Mylan-Lamotrigine 100 mg Tablet</td><td>0.88USD</td><td>tablet</td></tr><tr><td>Novo-Lamotrigine 100 mg Tablet</td><td>0.88USD</td><td>tablet</td></tr><tr><td>Pms-Lamotrigine 100 mg Tablet</td><td>0.88USD</td><td>tablet</td></tr><tr><td>Ratio-Lamotrigine 100 mg Tablet</td><td>0.88USD</td><td>tablet</td></tr><tr><td>Apo-Lamotrigine 25 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Mylan-Lamotrigine 25 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Novo-Lamotrigine 25 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Pms-Lamotrigine 25 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Ratio-Lamotrigine 25 mg Tablet</td><td>0.22USD</td><td>tablet</td></tr><tr><td>Lamictal 5 mg Chewable Tablet</td><td>0.18USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5698226</td><td>1995-07-29</td><td>2012-07-29</td></tr><tr><td>Canada</td><td>2277722</td><td>2001-03-27</td><td>2012-01-29</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>216-218 &#176;C (uncorr)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>2.5</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.88e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.87</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>1.93</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-2.7</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.98</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>5.87</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>90.71</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>66.62</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>23.1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Grahame Roy Lee, &#8220;Process for the preparation of lamotrigine.&#8221; U.S. Patent US5925755, issued January, 1981.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5925755&amp;tbm=pts" target="_blank">US5925755 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Backonja M: Neuromodulating drugs for the symptomatic treatment of neuropathic pain. Curr Pain Headache Rep. 2004 Jun;8(3):212-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15115640">Pubmed</a></li>
	<li>Barbosa L, Berk M, Vorster M: A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry. 2003 Apr;64(4):403-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12716240">Pubmed</a></li>
	<li>Jensen TS: Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6 Suppl A:61-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11888243">Pubmed</a></li>
	<li>Pappagallo M: Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther. 2003 Oct;25(10):2506-38. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14667954">Pubmed</a></li>
	<li>Tehrani SP, Daryaafzoon M, Bakhtiarian A, Ejtemaeemehr S, Sahraei H: The effects of lamotrigine on the acquisition and expression of morphine-induced place preference in mice. Pak J Biol Sci. 2009 Jan 1;12(1):33-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19579915">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00354" target="_blank">D00354 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3878" target="_blank">3878 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46505408" target="_blank">46505408 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3741.html" target="_blank">3741 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50031299" target="_blank">50031299 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=6367" target="_blank">6367 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL741" target="_blank">CHEMBL741 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000039" target="_blank">DAP000039 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450164" target="_blank">PA450164 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=2622" target="_blank">2622 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2622" target="_blank">2622 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2248232" target="_blank">2248232 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic/lamotrigine.htm" target="_blank">http://www.rxlist.com/cgi/generic/lamotrigine.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/lamotrigine.html" target="_blank">http://www.drugs.com/cdi/lamotrigine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Lamotrigine" target="_blank">Lamotrigine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N03AX09<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N03#N03">N03 &#8212; ANTIEPILEPTICS</a></li><li><a href="/atc/N03A#N03A">N03A &#8212; ANTIEPILEPTICS</a></li><li><a href="/atc/N03AX#N03AX">N03AX &#8212; Other antiepileptics</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:12.92</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00555.pdf?1265922795">show</a>(3.15 MB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00555.pdf?1265922735">show</a>(28.6 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00237">Butabarbital</a></td><td>Barbiturates like butabarbital may decrease the serum concentration of lamotrigine. There are separate patient management guidelines for patients age 12 and under and for patients older than 12 years of age. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00241">Butalbital</a></td><td>Barbiturates such as butalbital may decrease the serum concentration of lamotrigine. There are separate management guidelines for patients age 12 and under and for patients older than 12 years of age. Please refer to the current approved prescribing information for additional information. Monitor for decreased serum concentrations/therapeutic effects of lamotrigine if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Lamotrigine may increase the adverse effects of carbamazepine by increasing the concentration of its active metabolite, carbamazepine-epoxide. Carbamazepine may decrease the therapeutic effect of lamotrigine by increasing its metabolism. Lamotrigine doses should be adjusted accordingly. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinue or doses are changed.</td></tr><tr><td><a href="/drugs/DB00363">Clozapine</a></td><td>Lamotrigine increases the effect and toxicity of clozapine</td></tr><tr><td><a href="/drugs/DB00304">Desogestrel</a></td><td>The oral contraceptive decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>The oral contraceptive decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB04953">Ezogabine</a></td><td>In healthy adults, the AUCs of lamotrigine and ezogabine were both increased. The clinical significance of this is still unknown. Multiple doses of ezogabine also increase the clearance and decrease the terminal half-life of lamotrigine. </td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>The oral contraceptive decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB05246">Methsuximide</a></td><td>Methsuximide decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>The oral contraceptive decreases the effect of lamotrigine</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin may reduce levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin decreases levels of lamotrigine</td></tr><tr><td><a href="/drugs/DB00599">Thiopental</a></td><td>Thiopental may increase the metabolism and clearance of Lamotrigine. Monitor for decreased therapeutic effect of Lamotrigine if Thiopental is initiated.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Lamotrigine, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00313">Valproic Acid</a></td><td>Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>